Development and usability of a new subcutaneous auto-injector device to administer hydroxyprogesterone caproate to reduce the risk of recurrent preterm birth

por Travanty, Michael N, Calawa, Bryon, Shalaby, Waleed S, Jozwiakowski, Michael J, Haraldsen, Kyle B
Publicado 2018

Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedi...

por Monk, Bradley J., Herzog, Thomas J., Wang, George, Triantos, Spyros, Maul, Scott, Knoblauch, Roland, McGowan, Tracy, Shalaby, Waleed S.W., Coleman, Robert L.
Publicado 2020

Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin

por Jones, Robin L., Maki, Robert G., Patel, Shreyaskumar R., Wang, George, McGowan, Tracy A., Shalaby, Waleed S., Knoblauch, Roland E., von Mehren, Margaret, Demetri, George D.
Publicado 2019

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

por Jones, Robin L., Herzog, Thomas J., Patel, Shreyaskumar R., von Mehren, Margaret, Schuetze, Scott M., Van Tine, Brian A., Coleman, Robert L., Knoblauch, Roland, Triantos, Spyros, Hu, Peter, Shalaby, Waleed, McGowan, Tracy, Monk, Bradley J., Demetri, George D.
Publicado 2021